急性呼吸窘迫综合征炎症表型的时间稳定性:对早期糖皮质激素治疗及死亡率的临床意义
研究利用六项多中心随机对照试验的个体患者数据与生物标志物(开发队列n=1207,验证队列n=2751)建立开源AI临床分类器,仅用常规临床数据识别ARDS炎症表型,并在回顾性队列(n=5578)中从基线至第30天进行分类。分类器识别出2169例(39%)高炎症和3409例(61%)低炎症患者,30天死亡率分别为49%(1053例)和24%(826例)(p<0.001)。30天内,基线高炎症患者中49%(1072/2169)转为低炎症,基线低炎症患者中7%(229/3409)转为高炎症(p<0.001)。目标试验模拟显示高炎症患者使用糖皮质激素死亡率更低(IPW加权HR 0.81,95%CI 0.67-0.98,p=0.033),低炎症患者死亡率更高(IPW加权HR 1.26,95%CI 1.06-1.50,p=0.009);第3天时糖皮质激素的阳性反应仅持续存在于仍为高炎症的患者中(调整OR=0.51,95%CI 0.32-0.80,p=0.004)。
要点
- AI临床分类器仅用常规临床数据即可识别ARDS炎症表型:回顾性队列5578例中高炎症2169例(39%)、低炎症3409例(61%)。
- 高炎症表型30天死亡率49%(1053/2169),低炎症表型24%(826/3409),差异有统计学意义(p<0.001)。
- 表型随时间动态转变:基线高炎症者30天内49%(1072/2169)转为低炎症,基线低炎症者7%(229/3409)转为高炎症(p<0.001)。
- 糖皮质激素对死亡率的影响因表型而异:高炎症患者IPW加权HR 0.81(95%CI 0.67-0.98,p=0.033),低炎症患者IPW加权HR 1.26(95%CI 1.06-1.50,p=0.009)。
- 第3天糖皮质激素的阳性反应仅见于仍为高炎症的患者(调整OR=0.51,95%CI 0.32-0.80,p=0.004)。
适用人群与场景
- 六项多中心随机对照试验的个体患者数据与生物标志物:开发队列n=1207,验证队列n=2751。
- 回顾性队列(研究队列)n=5578,从基线至第30天进行分类。
研究设计与关键结果
- 研究类型:基于六项多中心随机对照试验个体患者数据与生物标志物的AI分类器开发与验证,并在回顾性队列中进行表型分类与目标试验模拟。
- AI临床分类器识别高炎症2169例(39%)与低炎症3409例(61%)。
- 30天死亡:高炎症1053例(49%),低炎症826例(24%)(p<0.001)。
- 30天内表型转变:基线高炎症49%(1072/2169)转为低炎症,基线低炎症7%(229/3409)转为高炎症(p<0.001)。
- 糖皮质激素与30天死亡率:高炎症患者IPW加权HR 0.81(95%CI 0.67-0.98,p=0.033);低炎症患者IPW加权HR 1.26(95%CI 1.06-1.50,p=0.009)。
- 第3天糖皮质激素阳性反应仅持续存在于仍为高炎症的患者(调整OR=0.51,95%CI 0.32-0.80,p=0.004)。
证据类型、等级与局限
- 证据类型:基于六项多中心随机对照试验个体患者数据的AI分类器开发与验证,结合回顾性队列与目标试验模拟。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,使用临床替代数据表征ARDS炎症表型可使医生在整个病程中监测患者并指导临床治疗。
- 作者认为,糖皮质激素可能对高炎症ARDS有益,对低炎症ARDS有害。
- 第3天糖皮质激素的阳性反应仅持续存在于仍为高炎症的患者中(调整OR=0.51,95%CI 0.32-0.80,p=0.004),提示需动态评估表型。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Inflammatory phenotypes of acute respiratory distress syndrome (ARDS) can predict patient outcomes and potentially response to treatment. The aim was to assess whether inflammatory phenotypes can be characterized over time using clinical surrogate data and used to guide therapy with corticosteroids.
METHODS: Individual patient data and biomarkers from six multicenter randomized controlled trials (development, n = 1207; validation, n = 2751) were analyzed to establish an open-source AI Clinical Classifier ( https://bostonmontpelliercare.shinyapps.io/AIClarity ) for inflammatory phenotypes of ARDS using routine clinical data. Then, patients from a retrospective cohort (investigation, n = 5578) underwent classification from baseline to day 30. A discrete-time Bayesian Markov model assessed temporal stability at 3-day intervals. A target trial emulation and longitudinal logistic regression assessed corticosteroid effect on 30-day mortality depending on phenotype.
RESULTS: The AI Clinical Classifier identified 2169 (39%) hyperinflammatory and 3409 (61%) hypoinflammatory patients. 1053 (49%) and 826 (24%) patients died within 30 days, respectively (p < 0.001). Over 30 days, 49%(1072/2169) of hyperinflammatory patients at baseline transitioned to hypoinflammatory, and 7%(229/3409) of hypoinflammatory patients at baseline transitioned to hyperinflammatory (p < 0.001). Phenotypes predicted response to corticosteroids, with lower mortality in hyperinflammatory patients (IPW-weighted hazard ratio [HR]: 0.81 [0.67-0.98], p = 0.033), and higher mortality in hypoinflammatory patients (IPW-weighted HR: 1.26 [1.06-1.50], p = 0.009). At day 3, a positive response to corticosteroids only persisted among patients who remained hyperinflammatory (adjusted odds ratio = 0.51, 95% CI 0.32-0.80, p = 0.004).
CONCLUSION: Characterization of inflammatory ARDS phenotypes using clinical surrogate data allows physicians to monitor patients throughout the course of the disease and guide clinical treatment. Corticosteroids may be beneficial in hyperinflammatory ARDS and harmful in hypoinflammatory ARDS.
参考来源
- Pensier J, Fosset M, Paschold BS, et al. Temporal stability of phenotypes of acute respiratory distress syndrome: clinical implications for early corticosteroid therapy and mortality. Intensive Care Med. 2025. PMID: 40839098. doi:10.1007/s00134-025-08089-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。